
Agranulocytosis induced by metamizole and its management with granulocyte growth factor
Author(s) -
Dušica Čeleketić,
Ana Trpković,
Zorica Cvetković
Publication year - 2005
Publication title -
vojnosanitetski pregled
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.123
H-Index - 19
eISSN - 2406-0720
pISSN - 0042-8450
DOI - 10.2298/vsp0501079c
Subject(s) - metamizole , medicine , dyscrasia , neutropenia , leukopenia , hematopoietic growth factor , antibiotics , haematopoiesis , drug , intensive care medicine , immunology , analgesic , pharmacology , chemotherapy , bone marrow , stem cell , plasma cell , biology , microbiology and biotechnology , genetics
Drug-induced agranulocytosis was defined as a severe selective neutropenia caused by an unexpected drug reaction. Metamizole was the most common nonopioid analgesic drug associated with agranulocytosis. It was also associated with combined blood dyscrasias and other severe immunologic disorders. The risk of agranulocytosis by metamizole seemed to be considerably higher than estimated formerly. Modern management with broad-spectrum antibiotics and haematopoietic growth factors reduced the mortality in those patients. Two cases of agranulocytosis caused by metamizole were reported.